Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Analyst Ratings
Hold
6 Buy
15 Hold
5 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SRPT Stock 12 Month Forecast
Average Price Target
$22.91
▼(-2.01% Downside)
| Highest Price Target$80.00 | Average Price Target$22.91 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Oppenheimer
$37
Buy
58.25%
Upside
Reiterated
10/09/25
Jefferies
$35
Buy
49.70%
Upside
Reiterated
10/08/25
RBC Capital
$14→$16
Hold
-31.57%
Downside
Reiterated
10/08/25
Mizuho Securities
$19
Hold
-18.73%
Downside
Reiterated
10/06/25
Evercore ISI
$17
Hold
-27.29%
Downside
Reiterated
09/23/25
Cantor Fitzgerald
$14
Hold
-40.12%
Downside
Reiterated
09/22/25
Guggenheim
$22
Buy
-5.90%
Downside
Reiterated
09/15/25
Bank of America Securities
$16
Sell
-31.57%
Downside
Reiterated
09/15/25
Leerink Partners
$12→$15
Hold
-35.84%
Downside
Reiterated
09/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)We expect preliminary single ascending dose (SAD) data with in myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), respectively, sometime in the second half of this year. The company was previously planning to hold an R&D Day, which is when we expected these results; however, this was canceled. Thus, it remains difficult to know exactly when in the second half data could be disclosed. Between the cancelation of the R&D Day, the monetization of the ARWR stock (here), and the lead time other sponsors have, it is difficult to gain much excitement (or confidence) ahead of the SAD data. However, we acknowledge that investors have gotten excited about early- stage data for other sponsors and best-in-class results could provide a much-needed lift to SRPT shares.
Deutsche Bank
$12
Sell
-48.67%
Downside
Reiterated
08/27/25
J.P. Morgan
$24→$18
Hold
-23.01%
Downside
Reiterated
08/26/25
H.C. Wainwright
$5
Sell
-78.61%
Downside
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Barclays
$22
Hold
-5.90%
Downside
Reiterated
08/21/25
Morgan Stanley
$20
Hold
-14.46%
Downside
Reiterated
08/21/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Oppenheimer
$37
Buy
58.25%
Upside
Reiterated
10/09/25
Jefferies
$35
Buy
49.70%
Upside
Reiterated
10/08/25
RBC Capital
$14→$16
Hold
-31.57%
Downside
Reiterated
10/08/25
Mizuho Securities
$19
Hold
-18.73%
Downside
Reiterated
10/06/25
Evercore ISI
$17
Hold
-27.29%
Downside
Reiterated
09/23/25
Cantor Fitzgerald
$14
Hold
-40.12%
Downside
Reiterated
09/22/25
Guggenheim
$22
Buy
-5.90%
Downside
Reiterated
09/15/25
Bank of America Securities
$16
Sell
-31.57%
Downside
Reiterated
09/15/25
Leerink Partners
$12→$15
Hold
-35.84%
Downside
Reiterated
09/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)We expect preliminary single ascending dose (SAD) data with in myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), respectively, sometime in the second half of this year. The company was previously planning to hold an R&D Day, which is when we expected these results; however, this was canceled. Thus, it remains difficult to know exactly when in the second half data could be disclosed. Between the cancelation of the R&D Day, the monetization of the ARWR stock (here), and the lead time other sponsors have, it is difficult to gain much excitement (or confidence) ahead of the SAD data. However, we acknowledge that investors have gotten excited about early- stage data for other sponsors and best-in-class results could provide a much-needed lift to SRPT shares.
Deutsche Bank
$12
Sell
-48.67%
Downside
Reiterated
08/27/25
J.P. Morgan
$24→$18
Hold
-23.01%
Downside
Reiterated
08/26/25
H.C. Wainwright
$5
Sell
-78.61%
Downside
Reiterated
08/25/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Barclays
$22
Hold
-5.90%
Downside
Reiterated
08/21/25
Morgan Stanley
$20
Hold
-14.46%
Downside
Reiterated
08/21/25
Best Analysts Covering Sarepta Therapeutics
1 Month
xxx
Success Rate
24/38 ratings generated profit
Average Return
+7.37%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +7.37% per trade.
3 Months
xxx
Success Rate
22/38 ratings generated profit
Average Return
+7.71%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.71% per trade.
1 Year
Success Rate
20/38 ratings generated profit
Average Return
+10.90%
reiterated a buy rating 25 days ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +10.90% per trade.
2 Years
xxx
Success Rate
17/38 ratings generated profit
Average Return
+8.84%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 44.74% of your transactions generating a profit, with an average return of +8.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SRPT Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
50
45
30
18
7
Buy
10
10
7
3
2
Hold
38
79
93
84
37
Sell
1
12
18
18
7
Strong Sell
1
4
8
7
4
total
100
150
156
130
57
Each month's total comprises the sum of three months' worth of ratings.
SRPT Financial Forecast
SRPT Stock Forecast FAQ
What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 22.91.
What is SRPT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for SRPT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SRPT a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold which is based on 6 buy ratings, 15 hold ratings and 5 sell ratings.
What is Sarepta Therapeutics’s price target?
The average price target for Sarepta Therapeutics is 22.91. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents -2.01% Decrease from the current price of $23.38.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents -2.01% Decrease from the current price of $23.38.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 26 Wall Streets Analysts.
How can I buy shares of SRPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.